Immune profiling in a randomized phase II trial of acalabrutinib and pembrolizumab (PA) versus pembrolizumab (P) for patients with metastatic urothelial cancer (mUC)

被引：0
|
作者：
Zhang, Tian
Staats, Janet S.
Chan, Cliburn
Harrison, Michael Roger
O'Donnell, Peter H.
Batich, Kristen A.
Chen, Tianling
Krejsa, Cecile
Izumi, Raquel
George, Daniel J.
Weinhold, Kent J.
机构：
[1] Duke Univ, Med Ctr, Durham, NC USA
[2] Duke Univ, Duke Canc Inst, Med Ctr, Durham, NC USA
[3] Univ Chicago, Comprehens Canc Ctr, Chicago, IL 60637 USA
[4] ICON Dev Soult, Palo Alto, CA USA
[5] Acerta Pharma, Redwood City, CA USA
[6] Duke Univ, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.4533
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4533
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182.
    Galsky, Matt D.
    Pal, Sumanta K.
    Mortazavi, Amir
    Milowsky, Matthew I.
    George, Saby
    Gupta, Sumati
    Fleming, Mark T.
    Dang, Long H.
    Geynisman, Daniel M.
    Walling, Radhika
    Alter, Robert S.
    Robin, Erwin L.
    Wang, Jue
    Gupta, Shilpa
    Chism, David D.
    Picus, Joel
    Philips, George
    Quinn, David I.
    Hahn, Noah M.
    Yu, Menggang
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [22] Testicular cancer: No activity of pembrolizumab in phase II trial
    Thoma C.
    Nature Reviews Urology, 2017, 14 (12) : 700 - 700
  • [23] Initial Experience of Pembrolizumab Therapy in Japanese Patients With Metastatic Urothelial Cancer
    Yasuoka, Shotaro
    Yuasa, Takeshi
    Nishimura, Noriko
    Ogawa, Masahiro
    Komai, Yoshinobu
    Numao, Noboru
    Yamamoto, Shinya
    Kondo, Yukihiro
    Yonese, Junji
    ANTICANCER RESEARCH, 2019, 39 (07) : 3887 - 3892
  • [24] Randomized Phase II Study of Pembrolizumab after SBRT versus Pembrolizumab Alone in Patients with Advanced NSCLC, Preliminary Results
    Theelen, Willemijn
    Lalezari, Ferry
    Van Den Heuvel, Michel
    Baas, Paul
    Peulen, Heike
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1453 - S1453
  • [25] Phase II trial of pembrolizumab in patients with brain metastases
    Brastianos, Priscilla Kaliopi
    Kim, Albert Eusik
    Giobbie-Hurder, Anita
    Lee, Eudocia Quant
    Lin, Nancy U.
    Overmoyer, Beth
    Wen, Patrick Y.
    Nayak, Lakshmi
    Cohen, Justine Vanessa
    Dietrich, Jorg
    Heist, Rebecca Suk
    Krop, Ian E.
    Lawrence, Donald P.
    Mayer, Erica L.
    Winer, Eric P.
    Shih, Helen Alice
    Oh, Kevin S.
    Cahill, Daniel P.
    Gerstner, Elizabeth R.
    Sullivan, Ryan J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] Pembrolizumab ± chemotherapy versus chemotherapy in advanced urothelial cancer: Phase 3 KEYNOTE-361 trial
    Powles, T.
    Gschwend, J. E.
    Loriot, Y.
    Bellmunt, J.
    Geczi, L.
    Vulsteke, C.
    Abdelsalam, M.
    Gafanov, R.
    Bae, W. K.
    Revesz, J.
    Yamamoto, Y.
    Anido, U.
    Su, W-P.
    Fleming, M.
    Markus, M.
    Feng, D.
    Poehlein, C.
    Alva, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [27] Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Final results
    Saltos, Andreas Nicholas
    Tanvetyanon, Tawee
    Creelan, Ben C.
    Shafique, Michael Rahman
    Antonia, Scott Joseph
    Haura, Eric B.
    Zheng, Hong
    Yu, Xiaoqing
    Saller, James Joseph
    Viracacha, Sebastian
    Thapa, Ram
    Boyle, Theresa A.
    Chen, Dung-Tsa
    Beg, Amer A.
    Gray, Jhanelle Elaine
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [28] Randomized phase 3 trial of IO102-IO103 plus pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic melanoma.
    Svane, Inge Marie
    Nair, Santosh M.
    Puzanov, Igor
    Robert, Caroline
    Hassel, Jessica Cecile
    Sandhu, Shahneen
    Christiansen, Anita Vedel
    Lowery, Kath
    Pemberton, Kristine
    Al Hajj, Mohammad
    Diede, Scott J.
    Ehrnrooth, Eva
    Eggermont, Alexander M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [29] A randomized phase 2 study of the Bruton tyrosine kinase (Btk) inhibitor acalabrutinib alone or with pembrolizumab for metastatic pancreatic cancer (mPC).
    Overman, Michael J.
    Lopez, Charles D.
    Benson, Al Bowen
    Neelapu, Sattva Swarup
    Mettu, Niharika B.
    Ko, Andrew H.
    Chung, Vincent M.
    Nemunaitis, John J.
    Reeves, James Andrew
    Bendell, Johanna C.
    Philip, Agop Philip
    Dalal, Rita
    Fardis, Maria
    Greer, Joy
    Wang, Xiaolin
    Inamdar, Sandeep
    Lannutti, Brian Joseph
    Rothbaum, Wayne
    Izumi, Raquel
    Javle, Milind M.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] Pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer: Methodology of phase 3 randomized trial
    Machiels, J. -P.
    Shin, S. W.
    Cohen, E.
    Harrington, K.
    Burtness, B.
    Gause, C.
    Swift, A.
    Swaby, R.
    Le Tourneau, C.
    ANNALS OF ONCOLOGY, 2015, 26 : 101 - 102
12345